AAD Roundup: Sun Sets Sights On Psoriasis As Competitive Pressures Mount
Executive Summary
Sun presented new data on its IL-23 inhibitor tildrakizumab, pending US FDA approval, at the American Academy of Dermatology meeting. Novartis and others – all competing for payers' dollars – also try to make the case for their products.
You may also be interested in...
Celgene’s Positive Phase III Data For Otezla In Scalp Psoriasis Could Yield Broader Label
Celgene estimates 80% of moderate-to-severe plaque psoriasis patients experience the disease in their scalps, meaning positive data in this indication could broaden the market opportunity for Otezla substantially. Novartis’ Cosentyx got scalp psoriasis added to its US label in February.
Interview: UCB Sees Bimekizumab As Good Long-Term Bet
UCB immunology chief Emmanuel Caeymaex tells Scrip that despite intense competition, the dual neutralization approach of bimekizumab in inhibiting both interleukin-17A and IL-17F could result in a treatment for psoriasis, psoriatic arthritis and ankylosing spondylitis that may produce faster and more durable clinical improvements than the drugs already on the market.
Celgene's Terrie Curran On Building, Broadening The I&I Franchise
Celgene has hit multiple roadblocks in building its inflammation and immunology (I&I) portfolio, but it has a lot of potential shots on goal to eventually help the company diversify its revenue beyond the cancer blockbuster Revlimid, starting with flagship product Otezla.